Eli Lilly and Company (NYSE:LLY) Price Target Raised to $723.00

Eli Lilly and Company (NYSE:LLY) had its price objective raised by The Goldman Sachs Group from $650.00 to $723.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has a neutral rating on the stock.

LLY has been the subject of a number of other research reports. Erste Group Bank upgraded shares of Eli Lilly and Company from a hold rating to a buy rating in a research note on Wednesday, April 3rd. TheStreet upgraded shares of Eli Lilly and Company from a c+ rating to a b rating in a research report on Friday, March 8th. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an overweight rating in a research report on Friday, February 16th. Barclays upped their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an overweight rating in a research report on Wednesday, February 7th. Finally, BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an outperform rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $728.05.

Eli Lilly and Company Trading Down 1.0 %

Shares of Eli Lilly and Company stock opened at $751.64 on Thursday. The company has a fifty day simple moving average of $761.77 and a 200-day simple moving average of $653.35. Eli Lilly and Company has a 12-month low of $367.35 and a 12-month high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock has a market cap of $714.18 billion, a price-to-earnings ratio of 129.59, a PEG ratio of 1.67 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.09 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 12.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the sale, the insider now directly owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 133,785 shares of company stock worth $86,537,034 in the last ninety days. Insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Hoxton Planning & Management LLC grew its stake in Eli Lilly and Company by 5.4% in the 1st quarter. Hoxton Planning & Management LLC now owns 1,128 shares of the company’s stock worth $878,000 after acquiring an additional 58 shares during the period. Sarasin & Partners LLP grew its stake in shares of Eli Lilly and Company by 11.4% during the 1st quarter. Sarasin & Partners LLP now owns 275,824 shares of the company’s stock valued at $214,580,000 after buying an additional 28,335 shares during the period. Evanson Asset Management LLC grew its stake in shares of Eli Lilly and Company by 5.3% during the 1st quarter. Evanson Asset Management LLC now owns 1,347 shares of the company’s stock valued at $1,048,000 after buying an additional 68 shares during the period. Dynamic Advisor Solutions LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,381 shares of the company’s stock valued at $11,966,000 after buying an additional 417 shares during the period. Finally, Fermata Advisors LLC grew its stake in shares of Eli Lilly and Company by 27.8% during the 1st quarter. Fermata Advisors LLC now owns 1,113 shares of the company’s stock valued at $866,000 after buying an additional 242 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.